AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04512612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy
Description: Participants randomised to Group A will undergo colonoscopic evaluation using dye-based chromoendoscopy
Study NCT04512612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: High definition white light colonoscopy
Description: Participants randomised to Group B will undergo colonoscopic evaluation using high definition white light endoscopy
Study NCT00030732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Capecitabine
Description: Gemcitabine + Capecitabine
Study NCT00030732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine alone
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-700C
Description: An add-on drug to conventional treatment of Hepatitis C
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: conventional treatment of Hepatitis C
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: conventional treatment of Hepatitis C
Study NCT00556504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, without acting ingredient.
Study NCT02447523 — intervention group
Intervention type: PROCEDURE
Intervention: Elective abdominal surgery
Study NCT02932241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Dialectical Behavior Therapy Skills Training
Description: 8, 50 minute skill training sessions made available to participants each week
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 75mg/m2 on Day 1
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel I.V at the dose of 75mg/m2 on Day 1
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin I.V at the dose of 80mg/m2 on Day 1
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine per os 50mg every Monday, Wednesday and Friday
Study NCT00705549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexate
Description: Pemetrexate I.V 500mg/m2 on Day 1
Study NCT01898559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Switch to smoking only little cigars
Description: Participants smoke only little cigars for 15 days.
Study NCT00457457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
Study NCT00457457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-369,003
Description: UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
Study NCT03636516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SWL
Description: extracorporeal shockwave lithotripsy apply
Study NCT04200352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-50717
Description: Oral tablets are 6, 9, and 12 mg.
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: asparaginase
Description: Given intramuscularly
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given intramuscularly
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: Given IV
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: Given IV over 6 hours
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV over 6 hours
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Given IV over 1-4 hours
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV over 1-4 hours
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV over 2 hours
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone hydrochloride
Description: Given IV over 1 hour
Study NCT00372593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV over 1 hour
Study NCT04690452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion Cultivation Training
Description: The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
Study NCT04690452 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Compassion Cultivation Training
Description: The Compassion Cultivation Training (CCT©) is an 8-week standardized meditation program conducted in groups of 15-20 participants and consisting of weekly 2 hour on-line sessions with 20-30 minutes of daily formal meditation practices and informal compassion practices. The CCT© program will be guided by a certified instructor form the Center for Compassion and Altruism Research and Education at Stanford University. The CCT© program comprises six sequential steps: 1) Settling the mind; 2) Loving-kindness and compassion for a loved one; 3) Self-directed loving-kindness and compassion; 4) Common humanity; 5) Cultivating compassion for others; and 6) Active compassion (Tonglen).
Study NCT04506138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg D1, D22
Study NCT04506138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection (Albumin Bound)
Description: Paclitaxel for Injection (Albumin Bound) 100mg/m\^2 D1, D8, D22, D29
Study NCT04506138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 D1, D22
Study NCT02702791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telecoaching
Description: Pedeometer based goals and telecoaching support
Study NCT02702791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary rehabilitation
Description: Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
Study NCT02702791 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pulmonary rehabilitation
Description: Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
Study NCT02212951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIOD-531
Study NCT02212951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix 75/25
Study NCT02212951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin R U-500
Study NCT01318980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet
Description: Taken orally
Study NCT01318980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] radiolabelled GSK2190915 solution
Description: Microtracer solution
Study NCT01318980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet administered to the proximal small bowel.
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Study NCT04290832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CO Intervention
Description: South Africa: Values clarification and attitude transformation (VCAT) workshop with conscientious objection content, debrief session(s) with termination of pregnancy (TOP) providers to give them an opportunity to share concerns/challenges, meeting(s) with facility mangers to facilitate continued support and provision of TOP care~Mexico: Training on abortion and conscientious objection law, posters on law, offer of legal assistance for abortion providers, scholarship to attend conference awarded on basis of quality of abortion care
Study NCT01318980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg milled tablet administered to the distal small bowel.
Description: Ground half of a 200mg tablet. Administered via Enterion capsule.
Study NCT01318980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg enteric-coated tablet.
Description: Taken orally
Study NCT04673396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norcantharidin Lipid Microsphere for Injection
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Study NCT04673396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norcantharidin Lipid Microsphere for Injection
Description: The test drug was added to 5% glucose injection to a final volume of 250 mL，and administered by instillation at a rate of 200 mL/h.~This product can be used alone or in combination with chemotherapy, and the dosage and time of administration vary with the chemotherapy regimen.
Study NCT04673396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Demethylcantharidate Injection
Description: Dissolve the reference drug with appropriate amount of sterile water for injection, and add 250 mL of 5% glucose injection for slow dripping.
Study NCT00612248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint
Description: Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
Study NCT03816293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Negative Pressure Wound Therapy
Description: Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
Study NCT03603262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
Study NCT01717924 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peri-operative chemotherapy
Description: Usual treatment strategy for gastric adenocarcinoma
Study NCT01717924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery first
Description: strategy with a surgical procedure first, without the usual peri-operative chemotherapy
Study NCT01651637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: synthetic surfactant (CHF5633)
Description: CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
Study NCT01001325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral influenza vaccine, 2009-2010
Description: 0.5 mL intramuscular
Study NCT01001325 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5 mL intramuscular
Study NCT02820493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vedolizumab
Study NCT01584440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-20
Description: AVP-923-20: 20 mg of dextromethorphan and 10 mg of quinidine
Study NCT01584440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT01584440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study NCT01584440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-923-30
Description: AVP-923-30: 30 mg of dextromethorphan and 10 mg of quinidine
Study NCT03212144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
Study NCT03212144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut Consumption
Description: Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
Study NCT01185080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Nasal spray solution, intranasal, three times weekly for one month
Study NCT01185080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray solution, intranasal, three times weekly for one month
Study NCT00441597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatine 80mg, during 3 days
Study NCT02393638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation and lecture
Description: Endoscopic sphincterotomy on simulator and lecture
Study NCT02393638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lecture
Description: Lecture
Study NCT02868073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN (high dose) Oral Vaccine Tablet
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
Study NCT02868073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VXA Placebo Tablets
Description: The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
Study NCT02868073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN (low dose) Oral Vaccine Tablet
Description: The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
Study NCT02193074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nusinersen
Description: Administered by intrathecal (IT) injection as specified in the treatment arm.
Study NCT02193074 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made
Study NCT03124563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
Study NCT03124563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation Intention Condition
Description: Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
Study NCT01185080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848 and placebo
Description: Nasal spray solution, intranasal, three times weekly for one month
Study NCT03196362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone + Metformin
Description: One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
Study NCT03196362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: One tablet of placebo will be given twice daily
Study NCT04241419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Walking
Description: Participants will then undergo a 12 session intervention, with two sessions scheduled per week for six weeks. These will be 45 minute sessions, including 15 minutes of a warm-up and cool-down period as well as 30 minutes of walking. The intervention will include various types of over ground walking and stair work.
Study NCT04542018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: a low FODMAP diet for 4 weeks
Description: low FODMAP diet for 4 weeks
Study NCT04273035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: Oral Buccolam
Study NCT04273035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IPAD
Description: Playing any game, film, clip or puzzle on a tablet till after induction of anesthesia
Study NCT00802945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: NKTR-102 given on a q14 day schedule
Study NCT00802945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Description: NKTR-102 given on a q21 day schedule
Study NCT02145013 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy by either open, laparoscopic or robotic procedures
Study NCT01562093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid nasal spray
Description: fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
Study NCT01562093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo nasal spray
Description: formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
Study NCT03952975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal bleeding
Description: Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
Study NCT01442103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normlgel Ag
Description: Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
Study NCT04279626 — intervention group
Intervention type: PROCEDURE
Intervention: LETS-M
Description: A 1.5-centimeter skin incision was made over the umbilicus, and the abdominal wall was opened layer by layer with an open method. A wound retractor (Alexis, 2-4 centimeter; Applied Medical Resources Corp., Rancho Santa Margarita, CA) was placed, and the glove port was set up, with a 10-millimeter trocar in the thumb over patient's right side, and a 5-millimeter trocar in the little finger over the left side. The pneumoperitoneum was established. A 10-millimeter rigid laparoscope was inserted via the 10-millimeter trocar and controlled by the assistant. The ancillary 5-millimeter port was made over the left lower abdomen under laparoscope inspection. The surgeon performed the surgery via the two 5-millimeter trocars.